Sehn, L. H., MacDonald, D., Rubin, S., Cantin, G., Rubinger, M., Lemieux, B., Basi, S., Imrie, K., Gascoyne, R. D., Sussman, J., Chen, B. E., Djurfeldt, M., Shepherd, L., Couban, S., & Crump, M. (2011). Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group. Journal of Clinical Oncology, 29(25), 3396-3401. https://doi.org/10.1200/JCO.2010.33.6594
Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group. / Sehn, Laurie H.; MacDonald, David; Rubin, Sheldon et al.
In:
Journal of Clinical Oncology, Vol. 29, No. 25, 01.09.2011, p. 3396-3401.
Research output: Contribution to journal › Article › peer-review
Sehn, LH, MacDonald, D, Rubin, S, Cantin, G, Rubinger, M, Lemieux, B, Basi, S, Imrie, K, Gascoyne, RD, Sussman, J, Chen, BE, Djurfeldt, M, Shepherd, L, Couban, S & Crump, M 2011, 'Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group', Journal of Clinical Oncology, vol. 29, no. 25, pp. 3396-3401. https://doi.org/10.1200/JCO.2010.33.6594
Sehn LH, MacDonald D, Rubin S, Cantin G, Rubinger M, Lemieux B et al. Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group. Journal of Clinical Oncology. 2011 Sept 1;29(25):3396-3401. doi: 10.1200/JCO.2010.33.6594
Sehn, Laurie H. ; MacDonald, David ; Rubin, Sheldon et al. / Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma : A phase II study by the National Cancer Institute of Canada clinical trials group. In: Journal of Clinical Oncology. 2011 ; Vol. 29, No. 25. pp. 3396-3401.
@article{7ad503bfb3ce40cab114bba4ae507482,
title = "Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma: A phase II study by the National Cancer Institute of Canada clinical trials group",
author = "Sehn, {Laurie H.} and David MacDonald and Sheldon Rubin and Guy Cantin and Morel Rubinger and Bernard Lemieux and Sanraj Basi and Kevin Imrie and Gascoyne, {Randy D.} and Jonathan Sussman and Chen, {Bingshu E.} and Marina Djurfeldt and Lois Shepherd and Stephen Couban and Michael Crump",
year = "2011",
month = sep,
day = "1",
doi = "10.1200/JCO.2010.33.6594",
language = "English",
volume = "29",
pages = "3396--3401",
journal = "Journal of Clinical Oncology",
issn = "0732-183X",
publisher = "American Society of Clinical Oncology",
number = "25",
}
TY - JOUR
T1 - Bortezomib added to R-CVP is safe and effective for previously untreated advanced-stage follicular lymphoma
T2 - A phase II study by the National Cancer Institute of Canada clinical trials group
AU - Sehn, Laurie H.
AU - MacDonald, David
AU - Rubin, Sheldon
AU - Cantin, Guy
AU - Rubinger, Morel
AU - Lemieux, Bernard
AU - Basi, Sanraj
AU - Imrie, Kevin
AU - Gascoyne, Randy D.
AU - Sussman, Jonathan
AU - Chen, Bingshu E.
AU - Djurfeldt, Marina
AU - Shepherd, Lois
AU - Couban, Stephen
AU - Crump, Michael
PY - 2011/9/1
Y1 - 2011/9/1
UR - http://www.scopus.com/inward/record.url?scp=80052739391&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=80052739391&partnerID=8YFLogxK
U2 - 10.1200/JCO.2010.33.6594
DO - 10.1200/JCO.2010.33.6594
M3 - Article
C2 - 21810681
AN - SCOPUS:80052739391
SN - 0732-183X
VL - 29
SP - 3396
EP - 3401
JO - Journal of Clinical Oncology
JF - Journal of Clinical Oncology
IS - 25
ER -
